Abstract
This small yet popular meeting attracted its usual enthusiastic group of neuropeptide devotees. The bulk of the material presented had already been published, but the symposium on neuropeptide Y (NPY) saw the first public disclosure of the sequence of the NPY Y5 receptor by Synaptic and heard the news that a non-peptide NPY receptor antagonist from Sanofi was moving into clinical development. Interesting sessions were held on the role of neuropeptides in drug and alcohol dependence and on the neurotrophic actions of peptides. This report is selective and deals with only some of the presentations made, which reflects the interests of the authors and is not a value judgement.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
